BGB 3111 in Combination With Obinutuzumab in Participants With B-Cell Lymphoid Malignancies
Status:
Completed
Trial end date:
2020-09-02
Target enrollment:
Participant gender:
Summary
This study evaluated the safety and preliminary efficacy of BGB-3111 (zanubrutinib) in
combination with obinutuzumab in participants with B-cell lymphoid malignancies.